Neogen stock
NEOGNASDAQNeogen Corporation, HealthcareISIN US6404911066
42Score 42 out of 100, Weak
Price and trend
64 / 100
Price history
+78% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 10% above it.
Since December 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 45).
The price is 17% below its 52-week high. Largest decline in 20 years: 91% (April 2021 to April 2025).
Chart figures for advanced users
- SMA 50$12.26
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$10.51
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)45
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$5.41
- The lowest closing price of the last twelve months.
- Resistance$13.98
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Neogen Corporation belongs to the Medical (Devices) industry (United States) and, with a market value of $2.53B, is number 36 of 90 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $870.4M (down 2.7% year on year) and a loss of $7.9M.
- For fiscal 2027, analysts expect on average revenue of $888.08M (up 2%) and adjusted earnings per share of $0.33 (up 4.2%).
Show more
- MEQIRI Score 42 out of 100 (Weak): rank 524 of 714 in Healthcare, median 53.
- Our model puts fair value at $5.69, with the price 104% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 22.6% a year through 2029 (estimates from 3 analysts).
Weaknesses
- DilutionShare count up 104% since 2021.Capital allocation 18
- Margin fallingOperating margin −2.5%, average of the prior years 8.4% (to 2025).Profitability 23
- Interest barely coveredOperating profit covers interest only 0.8 times.Stability 53
Its standout strength is momentum, while valuation and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
- price up very strongly over the past year
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $4.06 and expensive above $9.48 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 9.3%. At 10.3% the fair value would be $4.76, at 8.3% it would be $7.04.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 31 Aug 2026, revenue fell 0.3% on the twelve months before. Revenue has grown strongly since 2007, at around 13% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 47%, operating −2%, net −1%. Last 12 months: net −6%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 14 Jan 2027in 63 days
- Last reported
- 6 Oct 2026EPS reported $0.08 (expected $0.05)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 3.1% since 15 Oct 2026.
- Earnings per share
- $0.33+3.1%
- Revenue
- $888.08M+0.2%
- Earnings per share
- $0.44+9.9%
- Revenue
- $854.24M−2.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −10.2%Revenue guidance raised to $885 million to $890 million and adjusted EBITDA guidance to $181 million to $183 million.
“While it is still early in the fiscal year, we are raising our revenue guidance to $885 million to $890 million We are also raising our adjusted EBITDA guidance to $181 million to $183 million to reflect the higher expected revenue.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Oct 2026 (fiscal Q1 2027), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $10,404 in total. One insider sold, $114,676 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Neogen
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 42
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- AmbuAMBU-B.CO $3.41B70
- TransMedics GroupTMDX $3.2B57
- iRhythm TechnologiesIRTC $2.94B30
- GN Store NordGN.CO $2.67B55
- UFP TechnologiesUFPT $2.43B77
- ElektaEKTA-B.ST $2.29B56
- Drägerwerk AG & Co. KGaADRW3.DE $2.29B65
- Establishment Labs HoldingsESTA $2.11B41
ETFs that hold Neogen
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Rize Sustainable Future of Food UCITS ETFRIZF | 1.90% | 0.45% | €59.51M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.25% | 0.40% | €1.49B |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.15% | 0.30% | €2.28B |
Show 5 more
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.10% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.09% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.09% | 0.30% | €4.22B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.04% | 0.30% | €944.34M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.03% | 0.45% | €1.53B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 May 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2023)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.